Clinical research Coordinator
I can help with clinical research coordination topics! Could you let me know what specifically you need?
Asking for Preferences
What would you like help with as a Clinical Research Coordinator?
Asking for Preferences
Which GCP area do you need help with?
Great choice. Let me pull together a solid overview of GCP core principles and the ICH E6(R2) guideline, including what's changing with R3.
Searching sources...
Searching the Web
ICH E6 R3 GCP guidelines 2025 2026 updates
Searching the Web
ICH E6 R2 GCP core principles summary CRC clinical research coordinator
Reading Web Page
https://pharmaeducenter.com/blog/principles-of-ich-gcp
Here is a thorough breakdown of GCP core principles with the E6(R2) vs. E6(R3) comparison - exactly what you need as a CRC.
GCP Core Principles: ICH E6(R2) and E6(R3) for Clinical Research Coordinators
What is GCP?
Good Clinical Practice (GCP) is an international ethical and scientific quality standard for the design, conduct, recording, and reporting of clinical trials involving human subjects. The foundational document is the ICH E6 guideline, originally published in 1996 and revised over two major iterations.
The two pillars underlying everything in GCP are:
- Participant rights, safety, and well-being - ethics always come first
- Reliability and integrity of trial data - results must be trustworthy
ICH E6(R2) - The 13 Principles (2016)
E6(R2) was adopted in 2016 and remains the currently enforced standard in most jurisdictions. As a CRC, these are the principles you are tested on and held accountable to:
| # | Principle | What It Means in Practice |
|---|---|---|
| 1 | Ethical conduct per Declaration of Helsinki | All research must be ethically sound; IRB/IEC approval is mandatory before any trial activity |
| 2 | Benefits justify risks | Risk-benefit ratio must favor participants; documented in the protocol |
| 3 | Participant rights, safety, and well-being take priority | Always supersedes science or sponsor interests |
| 4 | Available nonclinical and clinical info supports the trial | Investigational products must have adequate prior data |
| 5 | Scientific soundness of the protocol | Protocol must be clear, detailed, and statistically valid |
| 6 | Compliance with protocol | Follow the protocol as approved; deviations must be documented and reported |
| 7 | Medical care of participants | A qualified physician must be responsible for medical decisions |
| 8 | Qualified staff | All staff must be trained and qualified for their roles |
| 9 | Freely given informed consent | Obtained before any trial procedure; must be ongoing |
| 10 | Data recording and reporting | All data must be recorded accurately and verifiably |
| 11 | Confidentiality of records | Participant identifiable information must be protected |
| 12 | Investigational product manufacturing per GMP | Product quality and handling per Good Manufacturing Practice |
| 13 | Quality systems for every aspect of the trial | Sponsor must implement quality assurance and quality control |
ICH E6(R3) - The 11 Principles (New Framework)
ICH E6(R3) consolidates the 13 principles into 11 high-level principles, reflecting how modern trials work - including decentralized trials, risk-based monitoring, and digital data. The two biggest additions are:
| # | Principle | Key Change from R2 |
|---|---|---|
| 1 | Ethical conduct | Unchanged - Declaration of Helsinki remains the foundation |
| 2 | Rights, safety, and well-being | Unchanged - still the top priority |
| 3 | Benefits justify risks | Unchanged |
| 4 | Qualified staff & medical oversight | Consolidates R2 principles 7 & 8 |
| 5 | Informed consent | Unchanged in intent; updated to reflect eConsent and remote participation |
| 6 | Quality by Design (NEW) | Quality must be built into trial design upfront, not checked for at the end. Focus on what matters most to trial outcomes |
| 7 | Proportionality (NEW) | Oversight and administrative burden should match the actual risk level. Low-intervention trials need less burden than first-in-human studies |
| 8 | Protocol compliance | Deviation handling clarified - safety always takes precedence; root cause and corrective action required |
| 9 | Data integrity & ALCOA++ | Expanded to cover all record formats including metadata and audit trails |
| 10 | Roles and responsibilities | Clearer delineation of sponsor, investigator, CRO, and CRC duties |
| 11 | Confidentiality | Unchanged in intent; updated for modern data protection laws (GDPR, HIPAA) |
The Two Key New Concepts You Need to Know
Quality by Design (QbD) / ICH E6(R3) Principle 6
- Identify Critical to Quality (CtQ) factors before the trial starts
- Ask: "What data is truly essential to patient safety and trial conclusions?"
- If a data point doesn't affect either, it should not be a burden on sites
- Linked to the Quality Management System (QMS) and risk-based monitoring
Proportionality / ICH E6(R3) Principle 7
- Monitoring intensity, documentation requirements, and oversight should scale with actual risk
- A Phase 4 observational study should not carry the same SOV burden as a Phase 1 oncology FIH trial
- This is why Risk-Based Monitoring (RBM) and centralized monitoring are now standard
ALCOA++ - The Data Integrity Standard
Every CRC must know this. All trial data must be:
| Letter | Standard |
|---|---|
| A | Attributable - who collected it and when |
| L | Legible - readable and permanent |
| C | Contemporaneous - recorded at time of observation |
| O | Original - first capture of data, not a copy |
| A | Accurate - correct and precise |
| +C | Complete |
| +C | Consistent |
| +E | Enduring - data preserved for required retention period |
| +A | Available - accessible for review and audit |
R3 adds Traceable - meaning changes to data must have an audit trail showing who changed what, when, and why.
E6(R2) vs. E6(R3) at a Glance
| Feature | E6(R2) | E6(R3) |
|---|---|---|
| Number of principles | 13 | 11 |
| Quality approach | Reactive QC | Proactive Quality by Design |
| Risk approach | General | Proportionality built in |
| Monitoring | Risk-based monitoring encouraged | RBM and centralized monitoring normalized |
| Decentralized trials | Not addressed | Explicitly accommodated |
| Data formats | Primarily paper/EDC | All formats including eSource, eConsent, wearables |
| Informed consent | Traditional | eConsent explicitly recognized |
CRC-Specific Compliance Takeaways
- Know your protocol cold - protocol compliance is a GCP principle, not just a site expectation
- Document everything in real time - ALCOA++ applies to your source documents and eCRF entries
- Never alter records without an audit trail - corrections must be single-line strikethrough, dated, initialed, with reason
- Informed consent is ongoing - re-consenting participants after protocol amendments is your responsibility
- Report deviations promptly - under R3, you must document what happened, why, and what was done to prevent recurrence
- Your qualifications must be current - GCP training, CV, and delegation log entries must be up to date before you perform any trial task
If you want to go deeper on any section - such as deviation reporting, delegation of authority logs, monitoring visit preparation, or the shift to eConsent - just ask.
This is a shared conversation. Sign in to Orris to start your own chat.